Vamil Divan discusses the recent news around the positive data, yet mixed results of phase 2 trials of Eli Lilly's promising Alzheimer's drug. Upcoming data must demonstrate high primary efficacy endpoint results, as well safety. Overall, Vamil remains encouraged by the mid to long term potential of the drug.
16 Mar 2021
The Watch List
04 Jan 2022
The Watch List
22 Feb 2022
The Watch List
20 Dec 2021
Market On Close
22 Dec 2021
Trading 360
18 Jan 2022
Trading 360
10 Jan 2022